Physician profile
Isha A Godbold
NPI 1306551593
$1,110.43
in general payments reported to CMS, 2019-2025
12 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $895 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $256.72 | 2024-2025 | Camzyos |
| Medtronic, INC. | $180.46 | 2024-2025 | Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Amgen INC. | $171.62 | 2024 | Repatha |
| Scpharmaceuticals INC. | $110.67 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $109.23 | 2024 | Farxiga |
| Boston Scientific Corporation | $70.79 | 2024-2025 | Watchman Flx, Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $63.02 | 2024 | Arcalyst |
| Abiomed | $43.18 | 2024 | Impella |
| Cardiva Medical, INC. | $31.78 | 2024 | Ensoetm |
| Janssen Pharmaceuticals, INC | $31.50 | 2024 | Xarelto |
| Recor Medical INC | $25.47 | 2025 | Paradise Ultrasound Renal Denervation System |
| Merck Sharp & Dohme LLC | $15.99 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isha Godbold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.